PT - JOURNAL ARTICLE AU - Jochum, Simon AU - Kirste, Imke AU - Hortsch, Sayuri AU - Grunert, Veit Peter AU - Legault, Holly AU - Eichenlaub, Udo AU - Kashlan, Basel AU - Pajon, Rolando TI - Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial AID - 10.1101/2021.10.04.21264521 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.04.21264521 4099 - http://medrxiv.org/content/early/2021/10/06/2021.10.04.21264521.short 4100 - http://medrxiv.org/content/early/2021/10/06/2021.10.04.21264521.full AB - Background The ability to quantify an immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential. This study assessed the clinical utility of the quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay (ACOV2S) using samples from the 2019-nCoV vaccine (mRNA-1273) phase 1 trial (NCT04283461).Methods Samples from 30 healthy participants, aged 18–55 years, who received two injections with mRNA-1273 at a dose of 25 μg (n=15) or 100 μg (n=15), were collected at Days 1 (first vaccination), 15, 29 (second vaccination), 43 and 57. ACOV2S results (shown in U/mL – equivalent to BAU/mL per the first WHO international standard) were compared with results from ELISAs specific to antibodies against the Spike protein (S-2P) and the receptor binding domain (RBD) as well as neutralization tests including nanoluciferase (nLUC80), live-virus (PRNT80), and a pseudovirus neutralizing antibody assay (PsVNA50).Results RBD-specific antibodies were already detectable by ACOV2S at the first time point of assessment (d15 after first vaccination), with seroconversion before in all but 2 participants (25 μg dose group); all had seroconverted by Day 29. Across all post-baseline visits, geometric mean concentration of antibody levels were 3.27–7.48-fold higher in the 100 μg compared with the 25 μg dose group. ACOV2S measurements were highly correlated with those from RBD ELISA (Pearson’s r=0.938; p<0.0001) and S-2P ELISA (r=0.918; p<0.0001). For both ELISAs, heterogeneous baseline results and smaller increases in antibody levels following the second vs first vaccination compared with ACOV2S were observed. ACOV2S showed absence of any baseline noise indicating high specificity detecting vaccine-induced antibody response. Moderate–strong correlations were observed between ACOV2S and neutralization tests (nLUC80 r=0.933; PsVNA50, r=0.771; PRNT80, r=0.672; all p≤0.0001).Conclusion The Elecsys Anti-SARS-CoV-2 S assay (ACOV2S) can be regarded as a highly valuable method to assess and quantify the presence of RBD-directed antibodies against SARS-CoV-2 following vaccination, and may indicate the presence of neutralizing antibodies. As a fully automated and standardized method, ACOV2S could qualify as the method of choice for consistent quantification of vaccine-induced humoral response.Competing Interest StatementSimon Jochum, Imke Kirste, Sayuri Hortsch, Veit Peter Grunert and Udo Eichenlaub are employees of Roche Diagnostics. Basel Kashlan is an employee of PPD, Inc. Holly Legault and Rolando Pajon are employees of Moderna, Inc.Clinical TrialNCT04283461Funding StatementThis study utilized samples obtained under NCT04283461 funded by NIAID, National Institutes of Health (NIH), Bethesda MD USA. Moderna provided mRNA-1273 samples from their phase 1 trial for this study but did not provide any financial support. The phase 1 trial was supported by the NIAID, National Institutes of Health (NIH), Bethesda MD USA, under award numbers UM1AI148373 (Kaiser Washington), UM1AI148576 (Emory University), UM1AI148684 (Emory University), UM1Al148684-01S1 (Vanderbilt University Medical Center), and HHSN272201500002C (Emmes); by the National Center for Advancing Translational Sciences, NIH, under award number UL1 TR002243 (Vanderbilt University Medical Center); and by the Dolly Parton COVID-19 Research Fund (Vanderbilt University Medical Center).This analysis was funded by Roche Diagnostics GmbH (Penzberg, Germany). Editorial support was provided by Jade Drummond of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Roche Diagnostics International Ltd (Rotkreuz, Switzerland).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was granted by the Advarra institutional review board for the phase 1 trial and the diagnostic protocol under which the existing samples were tested.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors are committed to sharing data supporting the findings of eligible studies. Access to de-identified patient-level data and supporting clinical documents with qualified external researchers may be available upon request once the trial is complete.